Spectranetics Announces Third Quarter 2016 Conference Call and Upcoming Webcast at the Transcatheter Cardiovascular Therapeut...
October 06 2016 - 4:05PM
The Spectranetics Corporation (Nasdaq:SPNC) today announced that
the Company will release third quarter 2016 financial results after
the market close on Thursday, October 27, 2016. Company management
will host a conference call beginning at 2:30 p.m. Mountain Time
(4:30 p.m. Eastern Time) to discuss the results. The dial-in for
the conference call is (877) 561-2747 for domestic callers or (973)
409-9689 for international callers, and the Conference ID is
89698306. There will also be a live webcast of the call on the
investor relations section of the Company’s website at
www.spectranetics.com, which will be available on the Company’s
website for 14 days following the completion of the call.
Additionally, the Company announced that it will host a
physician panel and Q&A session with Company management at the
Transcatheter Cardiovascular Therapeutics conference in Washington,
D.C., on November 2, 2016, following the release of the ILLUMENATE
Pivotal study. The event will begin at 10:00 a.m. Eastern Time.
Space will be limited and you must RSVP to
investor.relations@spnc.com to reserve a seat. There will also be a
live webcast of the event on the investor relations section of the
Company’s website at www.spectranetics.com, which will be available
on the Company’s website for 14 days following the event.
About
Spectranetics
The Spectranetics Corporation develops, manufactures, markets and
distributes medical devices used in minimally invasive procedures
within the cardiovascular system. The Company's products are
available in over 65 countries and are used to treat arterial
blockages in the heart and legs and in the removal of pacemaker and
defibrillator leads.
The Company's Vascular Intervention (VI) products include a
range of laser catheters for ablation of blockages in arteries
above and below the knee, the AngioSculpt scoring balloon used in
both peripheral and coronary procedures, and the Stellarex
drug-coated balloon peripheral angioplasty platform, which received
European CE mark approval in December 2014. The Company also
markets support catheters to facilitate crossing of peripheral and
coronary arterial blockages, and retrograde access and guidewire
retrieval devices used in the treatment of peripheral arterial
blockages, including chronic total occlusions. The Company markets
aspiration and cardiac laser catheters to treat blockages in the
heart.
The Lead Management (LM) product line includes excimer laser
sheaths, dilator sheaths, mechanical sheaths and accessories for
the removal of pacemaker and defibrillator cardiac leads.
For more information, visit www.spectranetics.com.
Investor Relations Contacts
Zach Stassen
Investor.relations@spnc.com
(719) 447-2292
Michaella Gallina
Investor.relations@spnc.com
(719) 447-2417
The Spectranetics Corp. (MM) (NASDAQ:SPNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
The Spectranetics Corp. (MM) (NASDAQ:SPNC)
Historical Stock Chart
From Apr 2023 to Apr 2024